DuoGenic StemCells corporation

Peripheral Blood Cell Purification (PCP) technology is an exclusive patented technique developed by DuoGenic StemCells corporation. It concentrates and purifies mononuclear cells from autologous peripheral blood, which can differentiate into M2 macrophages with anti-inflammatory and tissue repair functions, achieving cellular therapeutic effects. PCP therapy has been proven by research to have the effect of initially inhibiting inflammation and secreting type II collagen. Clinical trials in conditions such as osteoarthritis have shown relief of patient pain and restoration of mobility, with effects lasting for over two years.